全球支氣管擴張劑市場：依藥物類別、給藥途徑、適應症、通路及地區分類

全球支氣管擴張劑市場預計到 2026 年將達到 237.8 億美元，預計到 2033 年將達到 313 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 4.0%。

支氣管擴張劑是能夠擴張肺部氣道、使呼吸更順暢的藥物。它們透過放鬆和擴張支氣管周圍的平滑肌發揮作用，從而減輕氣喘和慢性阻塞性肺病（COPD）等呼吸系統疾病引起的喘息、咳嗽和呼吸困難等症狀。支氣管擴張劑分為「短效」和「長效」兩種。短效支氣管擴張劑用於暫時緩解突發性呼吸困難，而長效支氣管擴張劑則用於長期控制氣喘和COPD患者的呼吸困難，或增強糖皮質激素在氣喘中的療效。抗膽鹼能藥物（也稱為抗毒蕈鹼藥物）主要用於治療COPD，但部分抗膽鹼能藥物也用於治療氣喘。抗膽鹼能藥物透過阻斷膽鹼能神經來擴張氣道。支氣管擴張劑的副作用因特定藥物而異。常見副作用包括手部震顫、頭痛、肌肉痙攣、噁心嘔吐和腹瀉。

市場動態：

全球支氣管擴張劑市場成長的主要促進因素包括：老年人口不斷增加，呼吸系統疾病盛行率上升；都市區環境污染日益嚴重；以及人們對氣喘和慢性阻塞性肺病（COPD）有效管理的認知不斷提高。然而，替代療法的存在、長期使用支氣管擴張劑的副作用以及重磅藥物專利到期等因素預計將抑制市場成長。聯合治療的研發，即同時使用兩種或多種藥物，為市場參與者創造了新的機會。此外，人們越來越重視預防性吸入療法以更好地控制呼吸症狀，這將推動未來市場需求的成長。

本研究的主要特點：

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究基於以下參數，對全球支氣管擴張劑市場的主要參與者進行了概況分析：公司概況、產品系列、關鍵亮點、財務績效和策略。本研究涵蓋的主要參與者包括葛蘭素史克（GSK plc）、Astra Zeneca）、邁蘭（Mylan NV）、默克（Merck & Co.）、太陽製藥（Sun Pharmaceutical Industries）、格蘭馬克製藥（Glenmark Pharmaceuticals）、諾華（Novartis AGY Industries）、格蘭馬克製藥（Glenmark Pharmaceuticals）、諾華（Novartis AGt）、勃林格西瓦）（Boar G影響）國）、西普拉（Cipla）、Sunovion Pharmaceuticals、賽諾菲（Sanofi）和Inoviva。
• 本報告提供的見解將有助於各公司的行銷負責人和經營團隊就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份「全球支氣管擴張劑市場報告」旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用全球支氣管擴張劑市場分析中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 產品核准數量增加
  • 嚴格的法規環境
  • 擴大宣傳宣傳活動
• 主要亮點
• 監管趨勢
• 市場趨勢
• 管道分析
• 產品上市及核准
• PEST分析
• 波特的分析
• 流行病學
• 治療流程（病患進展）
• 治療方案分析
• 主要市場參與者的新投資
• 價格分析
• 疾病意識計劃
• 對治療的安全性和有效性進行分析
• 併購和合作

第4章 全球支氣管擴張劑市場：依藥物類別分類，2021-2033年

• BETA-腎上腺素能支氣管擴張劑
• 黃嘌呤衍生物
• 抗膽鹼能支氣管擴張劑

第5章 全球支氣管擴張劑市場：依給藥途徑分類，2021-2033年

• 口服
• 鼻內（吸入型）
• 注射藥物

第6章 全球支氣管擴張劑市場：依適應症分類，2021-2033年

• 氣喘
• 慢性阻塞性肺病（COPD）
• 其他（例如，慢性支氣管炎）

第7章 全球支氣管擴張劑市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第8章 全球支氣管擴張劑市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第9章 競爭情勢

• 公司簡介
  • GSK plc.
  • Mylan NV
  • Mylan NV
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Sunovion Pharmaceuticals Inc.
  • Sanofi
  • Innoviva
• 分析師意見

第10章

• 參考
• 調查方法
• 關於本公司

Global Bronchodilators Market is estimated to be valued at USD 23.78 Bn in 2026 and is expected to reach USD 31.30 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.0% from 2026 to 2033.

Bronchodilators are medications that help open up the airways in the lungs to allow for easier breathing. They work by relaxing and dilating the smooth muscles surrounding the bronchial tubes, thus reducing wheezing, coughing, shortness of breath and other symptoms associated with respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be either short-acting used as short-term relief from sudden, unexpected attacks of breathlessness or long-acting used regularly to help control breathlessness in asthma and COPD, and increase the effectiveness of corticosteroids in asthma. Anticholinergics (also known as antimuscarinics) are mainly used to treat COPD, but a few can also be used for asthma. Anticholinergics cause the airways to widen by blocking the cholinergic nerves. The side effects of bronchodilators can vary, depending on the specific medication. General side effects of bronchodilators include trembling, particularly in the hands, headache, muscle cramps, nausea and vomiting, diarrhea, etc.

Market Dynamics:

The global bronchodilators market growth is driven by factors such as the growing geriatric population which is more susceptible to respiratory diseases, increased environmental pollution levels in both urban and rural areas, and rising awareness about proper management of asthma and COPD. However, availability of alternative treatment options, side effects associated with long term use of bronchodilators, and patent expires of blockbuster drugs are some of the key factors expected to restrain market growth. Development of combination therapies that can deliver two or more drugs simultaneously is opening new opportunities for players in this market. Moreover, greater emphasis on preventive inhalation therapies for better management of respiratory symptoms will drive future demand.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bronchodilators market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global bronchodilators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchodilators market

Detailed Segmentation:

• Global Bronchodilators Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
• Beta-adrenergic Bronchodilators
• Xanthine Derivatives
• Anticholinergic Bronchodilators
• Global Bronchodilators Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
• Oral
• Nasal (inhalable)
• Injectable
• Global Bronchodilators Market, By Indication (Revenue, USD Bn, 2021 - 2033)
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Others (Chronic bronchitis, etc.)
• Global Bronchodilators Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Top Companies in the Global Bronchodilators Market:
• GSK plc.
• AbbVie Inc.
• AstraZeneca
• Mylan N.V.
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Limited
• Novartis AG
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Sunovion Pharmaceuticals Inc.
• Sanofi
• Innoviva

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Indication
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing Product Approval
  • Stringent Regulatory Environment
  • Increasing Awareness Campaigns
• Key Highlights
• Regulatory Scenario
• Market Trends
• Pipeline Analysis
• Product Launch/Approval
• PEST Analysis
• PORTER's Analysis
• Epidemiology
• Treatment Algorithm (Patient Journey)
• Treatment Option Analysis
• New Investments by Major Market Players
• Pricing Analysis
• Disease Awareness Programs
• Treatment Safety and Efficacy Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Bronchodilators Market, By Drug Class, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Beta-adrenergic Bronchodilators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Xanthine Derivatives
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Anticholinergic Bronchodilators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

5. Global Bronchodilators Market, By Route of Administration, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Nasal (inhalable)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

6. Global Bronchodilators Market, By Indication, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Asthma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Chronic Obstructive Pulmonary Disease (COPD)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Others (Chronic bronchitis, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

7. Global Bronchodilators Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 201s9-2033, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

8. Global Bronchodilators Market, By Region, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2022 -2033
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profile
  • GSK plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sun Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Glenmark Pharmaceuticals Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim International GmbH
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Cipla Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sunovion Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Innoviva
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
• Analyst Views

10. Section

• References
• Research Methodology
• About us